Tumor necrosis factor biologics beyond psoriasis in dermatology

Expert Opinion on Biological Therapy

Volumn 11, Issue 10, 2011, Pages 1341-1359

  Patel, Raj ^a   Cafardi, John M ^b   Patel, Nital ^a   Sami, Naveed ^c   Cafardi, Jennifer A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Internal Medicine   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Adalimumab; Autoimmune blistering diseases; Autoimmune connective tissue diseases; Etanercept; Granulomatous diseases; Infliximab; Neutrophilic dermatoses; SAPHO syndrome; TNF ; Vasculitis

Indexed keywords

ADALIMUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GRAFT VERSUS HOST DISEASE; BEHCET DISEASE; BIOLOGICAL THERAPY; BULLOUS PEMPHIGOID; DERMATOMYOSITIS; DRUG EFFICACY; ERYTHEMA ANNULARE CENTRIFUGUM; GRANULOMA ANNULARE; HAILEY HAILEY DISEASE; HEADACHE; HISTOPLASMOSIS; HUMAN; INFECTION; INJECTION SITE REACTION; LUNG SARCOIDOSIS; MORPHEA; MUCOUS MEMBRANE PEMPHIGOID; MULTICENTRIC RETICULOHISTIOCYTOSIS; NECROBIOSIS LIPOIDICA; OFF LABEL DRUG USE; PSORIASIS; PSORIASIS VULGARIS; PYODERMA GANGRENOSUM; RASH; RETICULOHISTIOCYTOSIS; REVIEW; SAPHO SYNDROME; SARCOIDOSIS; SCLERODERMA; SUBCORNEAL PUSTULAR DERMATOSIS; SUPPURATIVE HIDRADENITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AGENTS; DERMATOLOGY; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 80052509500     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.590798     Document Type: Review

References (196)

1. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;11:154-8
2. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70
3. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-9 (Pubitemid 15195918)
4. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4 (Pubitemid 16239366)
5. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2
6. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-8 (Pubitemid 16039134)
7. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55 (Pubitemid 36278124)
8. Barbara JA, Van ostade X, Lopez A. Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Immunol Cell Biol 1996;74:434-43 (Pubitemid 26342128)
9. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/ tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20 (Pubitemid 40598088)
10. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11
11. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
12. Toussirot E, Pertuiset E. [TNFalpha blocking agents and sarcoidosis: An update.]. Rev Med Interne 2010;31:828-837 (In French)
13. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005;9(6):296-302 (Pubitemid 44491079)
14. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124:2028-31 (Pubitemid 37433610)
15. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4 (Pubitemid 32280539)
16. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004;117:277-9 (Pubitemid 39092723)
17. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004;150:146-9 (Pubitemid 38234021)
18. Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003;60:426-30 (Pubitemid 36314369)
19. Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003;48:290-3 (Pubitemid 36232335)
20. Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004;328:173-5 (Pubitemid 39295865)
21. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2003;2:413-14
22. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology 2002;59:1660-1 (Pubitemid 35387087)
23. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004;63:318-20 (Pubitemid 38250677)
24. Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004;251:760-1 (Pubitemid 38824027)
25. Ulbricht KU, Stoll M, Bierwirth J, et al. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 2003;48:3542-3 (Pubitemid 37531922)
26. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31 (Pubitemid 32619280)
27. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005;53:788-91 (Pubitemid 41463847)
28. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005;141:910-11 (Pubitemid 41058083)
29. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71 (Pubitemid 40775543)
30. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85 (Pubitemid 36851350)
31. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-47
32. Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006;142:17-9 (Pubitemid 43107354)
33. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 2005;53:917 (Pubitemid 41501405)
34. Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology;220:234-7
35. Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48:883-6
36. Plotner AN, Mutasim DF. Successful treatment of disseminated granuloma annulare with methotrexate. Br J Dermatol 2010;163:1123-4
37. Adams BB, Mutasim DF. Colocalization of granuloma annulare and mid-dermal elastolysis. J Am Acad Dermatol 2003;48(2 Suppl):S25-7 (Pubitemid 36231882)
38. Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 2005;152:552-5 (Pubitemid 40547131)
39. Werchau S, Enk A, Hartmann M. Generalized interstitial granuloma annulare-response to adalimumab. Int J Dermatol 2010;49:457-460
40. Kolde G, Muche JM, Schulze P, et al. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 2003;206:180-1 (Pubitemid 36205293)
41. Cummins DL, Hiatt KM, Mimouni D, et al. Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy. Int J Dermatol 2004;43:852-4 (Pubitemid 39529950)
42. Zeichner JA, Stern DW, Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54(3 Suppl 2):S120-1 (Pubitemid 43243483)
43. Suarez-Amor O, Perez-Bustillo A, Ruiz-Gonzalez I, Rodriguez-Prieto MA. Necrobiosis lipoidica therapy with biologicals: an ulcerated case responding to etanercept and a review of the literature. Dermatology;221:117-21
44. Hu SW, Bevona C, Winterfield L, et al. Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: report of a case. Arch Dermatol 2009;145:437-9
45. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 2009;89:601-3
46. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149:1046-9 (Pubitemid 37541993)
47. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010;62:205-17
48. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003;139:1540-2 (Pubitemid 37523071)
49. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002;97:2155-6
50. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003;49(5 Suppl):S275-6 (Pubitemid 37314860)
51. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323-6
52. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005;16:58-61 (Pubitemid 40283328)
53. Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003;38:1000-4 (Pubitemid 37455790)
54. Lasocki A, Sinclair R, Foley P, Saunders H. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol 2010;51:186-190
55. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007;46:1287-91
56. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009;145:580-4
57. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010;146:501-4
58. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg 2009;13:221-5
59. Shankar S, Sterling JC, Rytina E. Pustular pyoderma gangrenosum. Clin Exp Dermatol 2003;28:600-3 (Pubitemid 37430878)
60. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003;30:97-107 (Pubitemid 36384853)
61. Gettler S, Rothe M, Grin C, Grant-Kels J. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol 2003;4:597-608 (Pubitemid 37108419)
62. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821-6 (Pubitemid 36959164)
63. McGowan JWt, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004;3:441-4
64. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005;152:1059-61 (Pubitemid 40704955)
65. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002;37:1108-10
66. Chan JL, Graves MS, Cockerell CJ, Pandya AG. Rapid improvement of pyoderma gangrenosum after treatment with infliximab. J Drugs Dermatol 2010;9:702-4
67. Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNFalpha drug - Etanercept. J Plast Reconstr Aesthet Surg 2008;61:431-3 (Pubitemid 351389367)
68. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat: published online 1 August 2010, doi:10.3109/09546631003797106
69. Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol 2009;15:2293-5
70. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis 2009;15:803-6
71. Nobeyama Y, Kamide R. Sweet's syndrome with neurologic manifestation: case report and literature review. Int J Dermatol 2003;42:438-43 (Pubitemid 36740750)
72. Weenig RH, Bruce AJ, McEvoy MT, et al. Neutrophilic dermatosis of the hands: four new cases and review of the literature. Int J Dermatol 2004;43:95-102 (Pubitemid 38256439)
73. Reuss-Borst MA, Pawelec G, Saal JG, et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993;84:356-8 (Pubitemid 23201715)
74. Yamauchi PS, Turner L, Lowe NJ, et al. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54(3 Suppl 2):S122-6 (Pubitemid 43243485)
75. Ambrose NL, Tobin AM, Howard D. Etanercept treatment in Sweet's syndrome with inflammatory arthritis. J Rheumatol 2009;36:1348-9
76. Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy. Acta Gastroenterol Belg 2005;68:376-9 (Pubitemid 41474747)
77. Vaccaro M, Cannavo SP, Guarneri B. Subcorneal pustular dermatosis and IgA lambda myeloma: a uncommon association but probably not coincidental. Eur J Dermatol 1999;9:644-6 (Pubitemid 30007022)
78. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon- Wilkinson disease). Arch Dermatol 2001;137:1571-4 (Pubitemid 34000904)
79. Grob JJ, Mege JL, Capo C, et al. Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol 1991;25:944-7
80. Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol 2008;33:229-33 (Pubitemid 351550656)
81. Berk DR, Hurt MA, Mann C, Sheinbein D. Sneddon-Wilkinson disease treated with etanercept: report of two cases. Clin Exp Dermatol 2009;34:347-51
82. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21 (Pubitemid 38294802)
83. Airo P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002;41:347-9 (Pubitemid 34537876)
84. Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab (anti-TNFalpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:1116 (Pubitemid 37323579)
85. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-5 (Pubitemid 34016214)
86. Docken WP. Treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2004;63:469; author reply 469-70
87. Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-4 (Pubitemid 36363453)
88. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002;206(5):496-501 (Pubitemid 36192908)
89. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-304 (Pubitemid 38924409)
90. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10 (Pubitemid 38451274)
91. Lamprecht P, Moosig F, Adam-Klages S, et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2004;63:1518-20 (Pubitemid 39433964)
92. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-32 (Pubitemid 35203539)
93. Mang R, Ruzicka T, Stege H. Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol 2004;51:321-2
94. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-7 (Pubitemid 35363806)
95. Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotizing vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008;67:1343-6
96. Morgan MD, Drayson MT, Savage CO, Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 2011;117:c89-97
97. Martinez-Taboada VM, Val-Bernal JF, Pesquera LC, et al. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 2006;35:322-3 (Pubitemid 44181187)
98. Clemente RE. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 2007;36:244-5; author reply 245 (Pubitemid 47174559)
99. Wendling D, Streit G, Lehuede G, et al. Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine 2006;73:215-16
100. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-4 (Pubitemid 30670501)
101. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31:1955-8 (Pubitemid 39336719)
102. Fujikawa K, Kawakami A, Hayashi T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol 2010;20:86-9
103. Juan A, Ribas B, Nadal C, Ros I. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept? J Rheumatol 2005;32:2061; author reply 2061-2 (Pubitemid 41429045)
104. McIlwain L, Carter JD, Bin-Sagheer S, et al. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003;36:411-13 (Pubitemid 36459137)
105. Lee A, Kasama R, Evangelisto A, et al. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006;12:249-51 (Pubitemid 44527045)
106. Livermore PA, Murray KJ. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology (Oxford) 2002;41:1450-2 (Pubitemid 36004326)
107. Giacalone B, D'Auria L, Bonifati C, et al. Decreased interleukin-7 and transforming growth factor-beta1 levels in blister fluids as compared to the respective serum levels in patients with bullous pemphigoid. Opposite behavior of TNF-alpha, interleukin-4 and interleukin-10. Exp Dermatol 1998;7:157-61 (Pubitemid 28419404)
108. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999;79:288-90 (Pubitemid 29302057)
109. Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993;34:3522-5 (Pubitemid 24011987)
110. Sacher C, Rubbert A, Konig C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002;46:113-15 (Pubitemid 34073488)
111. Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54(3 Suppl 2):S121-2 (Pubitemid 43243484)
112. Canizares MJ, Smith DI, Conners MS, et al. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006;142:1457-61 (Pubitemid 44790639)
113. Boussemart L, Jacobelli S, Batteux F, et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010;221:201-5
114. Bordignon M, Belloni-Fortina A, Pigozzi B, et al. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 2009;219(4):357-8
115. Fairclough RJ, Dode L, Vanoevelen J, et al. Effect of Hailey-Hailey disease mutations on the function of a new variant of human secretory pathway Ca2 +/Mn2+-ATPase (hSPCA1). J Biol Chem 2003;278:24721-30 (Pubitemid 37548629)
116. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006;54(3 Suppl 2):S139-42 (Pubitemid 43243490)
117. Zhu LJ, Yang X, Yu XQ. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol 2010; Published online 22 June 2010, doi: 10.1155/2010/465898
118. Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009;18:690-7
119. Matsumura R, Umemiya K, Sugiyama T, et al. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009;27:416-21
120. Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008;7:411-19
121. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:504-9
122. Schroder JO, Zeuner RA. Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges. Curr Drug Discov Technol 2009;6:252-5
123. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:91-8
124. Luong JM, Tan BT, Buchanan RR, Schachna L. Tumour necrosis factor inhibitor-related lupus: safety of switching agents. Clin Rheumatol 2010;29:551-3
125. Porfyridis I, Kalomenidis I, Psallidas I, et al. Etanercept-induced pleuropericardial lupus-like syndrome. Eur Respir J 2009;33:939-41
126. Martin JM, Ricart JM, Alcacer J, et al. Adalimumab-induced lupus erythematosus. Lupus 2008;17:676-8
127. Soforo E, Baumgartner M, Francis L, et al. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010;37:204-5
128. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009;84:979-84
129. Neradova A, Stam F, van den Berg JG, Bax WA. Etanercept-associated SLE with lupus nephritis. Lupus 2009;18:667-8
130. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48:716-20
131. Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-alpha processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010;19:38-43
132. Koca SS, Isik A, Ozercan IH, et al. Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 2008;47:172-5 (Pubitemid 351168226)
133. Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-5 (Pubitemid 30337246)
134. Diab M, Coloe JR, Magro C, Bechtel MA. Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 2010;146:601-4
135. Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009;68:1433-9
136. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007;25:23-8 (Pubitemid 46477481)
137. Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008;75:346-9 (Pubitemid 351450408)
138. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7 (Pubitemid 47068007)
139. Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol 2003;30:2725-7 (Pubitemid 37549361)
140. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9:239-46 (Pubitemid 29287259)
141. Kuru S, Inukai A, Liang Y, et al. Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 2000;99:585-8 (Pubitemid 30201324)
142. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9-16
143. Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-74 (Pubitemid 27200003)
144. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000;2:216-24
145. Shimizu T, Tomita Y, Son K, et al. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 2000;19:352-9
146. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10-5 (Pubitemid 36736963)
147. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008;47:877-80 (Pubitemid 351796377)
148. Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 2002;41:1194-5 (Pubitemid 35203552)
149. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6 (Pubitemid 351339402)
150. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):ii51-3 (Pubitemid 35221714)
151. Alokaily F, Alsaleh S, Al-Balawi M, Al-Rashidi S. Efficacy of infliximab on the acute attack of uveitis. Saudi Med J 2010;31:82-5
152. Takamoto M, Kaburaki T, Numaga J, et al. Long-term infliximab treatment for Behcet's disease. Jpn J Ophthalmol 2007;51:239-40 (Pubitemid 46889492)
153. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010;94:284-8
154. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007;51:191-6 (Pubitemid 46889493)
155. Ikewaki J, Kono H, Shinoda K, et al. Cystoid macular edema: possible complication of infliximab therapy in Behcet's disease. Case Report Ophthalmol 2010;1:14-19
156. Kasugai C, Watanabe D, Mizutani K, et al. Infliximab treatment of severe genital ulcers associated with Behcet disease. J Am Acad Dermatol 2010;62:162-4
157. Jalili A, Kinaciyan T, Barisani T, et al. Successful treatment of refractory Behcet's disease with the TNF-alpha blocker infliximab. Iran J Immunol 2009;6:55-8
158. Olivieri I, Latanza L, Siringo S, et al. Successful treatment of severe Behcet's disease with infliximab in an Italian Olympic athlete. J Rheumatol 2008;35:930-2 (Pubitemid 351747140)
159. Almoznino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behcet's disease: a case report and review of the literature. Clin Exp Rheumatol 2007;25(4 Suppl 45):S99-2102
160. Curigliano V, Giovinale M, Fonnesu C, et al. Efficacy of etanercept in the treatment of a patient with Behcet's disease. Clin Rheumatol 2008;27:933-6
161. Olivieri I, D' Angelo S, Padula A, et al. Successful treatment of recalcitrant genital ulcers of Behcet's disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 2009;27(2 Suppl 53):S112
162. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41 (Pubitemid 47061701)
163. Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008;272:99-105
164. Belzunegui J, Lopez L, Paniagua I, et al. Efficacy of infliximab and adalimumab inthe treatment of a patient with severe neuro-Behcet's disease. Clin Exp Rheumatol 2008;26(4 Suppl 50):S133-4
165. Cantarini L, Tinazzi I, Caramaschi P, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009;22:551-5
166. Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs 2005;19:211-31 (Pubitemid 41430157)
167. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649-54 (Pubitemid 38970556)
168. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:1352-9 (Pubitemid 39540573)
169. Nogueira MC, Azevedo AM, Pereira SC, et al. Anti-tumor necrosis factor-alpha for the treatment of steroid-refractory acute graft-versus-host disease. Braz J Med Biol Res 2007;40:1623-9
170. Thin L, Macquillan G, Adams L, et al. Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors. Liver Transpl 2009;15:421-6
171. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008;111:2470-5 (Pubitemid 351451462)
172. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002;73:665-7 (Pubitemid 34193637)
173. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768-76 (Pubitemid 37258330)
174. Drosou A, Kirsner RS, Welsh E, et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003;7:382-6 (Pubitemid 37500396)
175. Barth D, Harth W, Treudler R, Simon JC. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges 2009;7:1071-3
176. Muller H, Gattringer C, Zelger B, et al. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol 2008;59(5 Suppl):S65-70
177. Garcovich S, Di Giampetruzzi AR, Antonelli G, et al. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol 2010;24:881-4
178. Ruzzetti M, Saraceno R, Carboni I, et al. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol 2008;22:117-18
179. Davis KF, Wu JJ, Murase JE, et al. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007;143:1597-9 (Pubitemid 350277793)
180. Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008;158:642-4 (Pubitemid 351239177)
181. Cox V, Lesesky EB, Garcia BD, O'Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol 2008;59(5 Suppl):S113-14
182. Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol 2009;145:99-101
183. Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8 (Pubitemid 34774530)
184. Olivieri I, Padula A, Ciancio G, et al. Persistent efficacy of tumor necrosis factor alpha blockage therapy in SAPHO syndrome: comment on the article by Wagner, et al. Arthritis Rheum 2003;48:1467; author reply 1467-8 (Pubitemid 36554552)
185. Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne- pustulosishyperostosis- osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005;52(5 Suppl 1):S118-20
186. Sabugo F, Liberman C, Niedmann JP, et al. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 2008;27:533-5 (Pubitemid 351404307)
187. Moll C, Hernandez MV, Canete JD, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008;37:299-306 (Pubitemid 351389483)
188. Ben Abdelghani K, Dran DG, Gottenberg JE, et al. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 2010;37:1699-704
189. Minni J, Sarro R. A novel therapeutic approach to erythema annulare centrifugum. J Am Acad Dermatol 2006;54(3 Suppl 2):S134-5 (Pubitemid 43243488)
190. Goltz RW, Laymon CW. Multicentric reticulohistiocytosis of the skin and synovia; reticulohistiocytoma or ganglioneuroma. AMA Arch Derm Syphilol 1954;69:717-31
191. Kalajian AH, Callen JP. Multicentric reticulohistiocytosis successfully treated with infliximab: an illustrative case and evaluation of cytokine expression supporting anti-tumor necrosis factor therapy. Arch Dermatol 2008;144:1360-6
192. Lee MW, Lee EY, Jeong YI, et al. Successful treatment of multicentric reticulohistiocytosis with a combination of infliximab, prednisolone and methotrexate. Acta Derm Venereol 2004;84:478-9
193. Shannon SE, Schumacher HR, Self S, Brown AN. Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol 2005;32:565-7 (Pubitemid 40381434)
194. Lovelace K, Loyd A, Adelson D, et al. Etanercept and the treatment of multicentric reticulohistiocytosis. Arch Dermatol 2005;141:1167-8 (Pubitemid 41373972)
195. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment ofmulticentric reticulohistiocyt sis with etanercept. Arch Dermatol 2004;140:919-21 (Pubitemid 39062641)
196. Sellam J, Deslandre CJ, Dubreuil F, et al. Refractory multicentric reticulohistiocytosis treated by infliximab: two cases. Clin Exp Rheumatol 2005;23:97-9 (Pubitemid 40424766)